Seres Therapeutics (MCRB) EBITDA (2014 - 2026)

Seres Therapeutics has disclosed EBITDA across 13 years of filings, most recently posting -$21.3 million for Q2 2026.

• In Q2 2026, EBITDA rose 14.5% year-over-year to -$21.3 million; the TTM figure through Jun 2026 stood at -$84.0 million (up 23.69% YoY), while the FY2025 annual figure was -$94.0 million, up 22.54% from the prior year.
• EBITDA came in at -$21.3 million for Q2 2026 at Seres Therapeutics, down from -$20.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $49.5 million in Q2 2023 to a low of -$70.6 million in Q1 2023.
• Average EBITDA over 5 years is -$30.0 million, with a median of -$28.9 million recorded in 2024.
• The largest YoY upside for EBITDA was 178.21% in 2023 against a maximum downside of 2038.88% in 2023.
• Over 5 years, EBITDA stood at -$1.7 million in 2022, then sank by 2038.88% to -$37.0 million in 2023, then grew by 22.12% to -$28.8 million in 2024, then soared by 32.8% to -$19.4 million in 2025, then fell by 9.78% to -$21.3 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$21.3 million in Q2 2026, -$20.9 million in Q1 2026, and -$19.4 million in Q4 2025.